Ignite Creation Date:
2024-05-05 @ 10:18 PM
Last Modification Date:
2024-10-26 @ 10:16 AM
Study NCT ID:
NCT01072175
Status:
COMPLETED
Last Update Posted:
2019-07-05
First Post:
2010-02-12
Brief Title:
Investigate Safety Pharmacokinetics and Pharmacodynamics of GSK2118436 GSK1120212
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
An Open-Label Dose-Escalation Phase III Study to Investigate the Safety Pharmacokinetics Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2019-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was an open-label dose escalation study to investigate the safety pharmacokinetics pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination This study was designed in four parts In Part A the effect of repeat doses of GSK1120212 on the pharmacokinetics of single dose GSK2118436 was investigated prior to evaluating combination regimens In Part B the range of tolerated dose combinations was identified using a dose-escalation procedure In Part C different dose combinations of GSK2118436 and GSK1120212 were evaluated based on results from the dose escalation cohorts In Part D the pharmacokinetics and safety of GSK2118436 administered as HPMC capsules alone and in combination with GSK1120212 was evaluated
Detailed Description:
During Part A a cohort of subjects received a single dose of GSK2118436 alone Day 1 and then repeat doses of GSK1120212 for Day 2 through Day 15 The dose regimen of GSK1120212 were continuous dosing A second single dose of GSK2118436 was administered on Day 15 concomitantly with GSK1120212 Day 16 through Day 28 was a washout period during which no study medication was administered Starting on Day 29 subjects who elected to continue participation in the study were doses with GSK2118436 The dose of GSK2118436 after Day 29 might be altered based on emerging data from the first-time-in human study BRF112680 The dose might be increased to a dose level that has been completed and determined to be less than or equal to the maximum tolerated dose in that study
Part B of the study enrolled cohorts in escalating doses to identify a set of allowable doses to be expanded in Part C Subjects were enrolled in a 33 cohort design with provisional dose levels of both drugs The decision regarding escalation to the next dose levels of GSK1120212 and GSK2118436 was further guided by a Bayesian logistic regression model The first cohort started at low doses for both drugs Doses up to 300 mgday for GSK2118436 and up to 3 mg QD for GSK1120212 were studied The starting dose might be lowered based on emerging data from other studies and from Part A
Expansion cohorts enrolled in Part C at dose levels of GSK2118436 and GSK1120212 as defined in Part B One of the selected doses might include GSK2118436 administered as monotherapy at a tolerable dose less than or equal to the maximum tolerated dose determined in BRF112680 Part C was a randomized open-label Phase II portion of the study and consisted of expansion cohorts investigating 2 to 3 dose levels of GSK2118436 and GSK1120212 dosing in combination and GSK2118436 administered as monotherapy Subjects were assigned to treatment arms in a randomized fashion to compare tolerability and safety Population PK parameters clinical activity durability of response and safety of GSK2118436 and GSK1120212 dosed orally in combination and GSK2118436 as monotherapy were evaluated
Part D consisted of evaluation of the pharmacokinetics of GSK2118436 HPMC capsules administered as monotherapy and in combination with GSK1120212 Pharmacokinetics of GSK2118436 was assessed following a single dose on Day 1 and after repeat dosing Day 21 and compared between combination and monotherapy The pharmacokinetics of GSK1120212 was also be assessed Safety tolerability and clinical activity were evaluated in 4 dosing cohorts These cohorts might be expanded for additional safety data Subjects were randomized to different cohorts
Part B of the study enrolled cohorts in escalating doses to identify a set of allowable doses to be expanded in Part C Subjects were enrolled in a 33 cohort design with provisional dose levels of both drugs The decision regarding escalation to the next dose levels of GSK1120212 and GSK2118436 was further guided by a Bayesian logistic regression model The first cohort started at low doses for both drugs Doses up to 300 mgday for GSK2118436 and up to 3 mg QD for GSK1120212 were studied The starting dose might be lowered based on emerging data from other studies and from Part A
Expansion cohorts enrolled in Part C at dose levels of GSK2118436 and GSK1120212 as defined in Part B One of the selected doses might include GSK2118436 administered as monotherapy at a tolerable dose less than or equal to the maximum tolerated dose determined in BRF112680 Part C was a randomized open-label Phase II portion of the study and consisted of expansion cohorts investigating 2 to 3 dose levels of GSK2118436 and GSK1120212 dosing in combination and GSK2118436 administered as monotherapy Subjects were assigned to treatment arms in a randomized fashion to compare tolerability and safety Population PK parameters clinical activity durability of response and safety of GSK2118436 and GSK1120212 dosed orally in combination and GSK2118436 as monotherapy were evaluated
Part D consisted of evaluation of the pharmacokinetics of GSK2118436 HPMC capsules administered as monotherapy and in combination with GSK1120212 Pharmacokinetics of GSK2118436 was assessed following a single dose on Day 1 and after repeat dosing Day 21 and compared between combination and monotherapy The pharmacokinetics of GSK1120212 was also be assessed Safety tolerability and clinical activity were evaluated in 4 dosing cohorts These cohorts might be expanded for additional safety data Subjects were randomized to different cohorts
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None